372 related articles for article (PubMed ID: 23792029)
1. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF
J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.
Marcellin P; Buti M; Krastev Z; de Man RA; Zeuzem S; Lou L; Gaggar A; Flaherty JF; Massetto B; Lin L; Dinh P; Subramanian GM; McHutchison JG; Flisiak R; Gurel S; Dusheiko GM; Heathcote EJ
J Hepatol; 2014 Dec; 61(6):1228-37. PubMed ID: 25046847
[TBL] [Abstract][Full Text] [Related]
3. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.
Seto WK; Lam YF; Fung J; Wong DK; Huang FY; Hung IF; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2014 May; 29(5):1028-34. PubMed ID: 24325451
[TBL] [Abstract][Full Text] [Related]
4. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
6. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
Wong D; Littlejohn M; Edwards R; Jackson K; Revill P; Gaggar A; Kitrinos K; Subramanian M; Marcellin P; Buti-Ferret M; Janssen H; Gane E; Locarnini S; Thompson A
Liver Int; 2018 Oct; 38(10):1760-1769. PubMed ID: 29427368
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir
Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Fasano M; Maggi P; Leone A; Volpe A; Fiore JR; Angarano G; Santantonio TA
Dig Liver Dis; 2017 May; 49(5):530-534. PubMed ID: 28179096
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
Kim YJ; Sinn DH; Gwak GY; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
World J Gastroenterol; 2012 Dec; 18(47):6996-7002. PubMed ID: 23322999
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
15. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).
Lee HW; Park JY; Kim BK; Kim MY; Lee JI; Kim YS; Yoon KT; Han KH; Ahn SH
Clin Mol Hepatol; 2016 Dec; 22(4):443-449. PubMed ID: 27880997
[TBL] [Abstract][Full Text] [Related]
18. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
Ahn SS; Chon YE; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
Clin Mol Hepatol; 2014 Sep; 20(3):261-6. PubMed ID: 25320729
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
